Colrain Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Colrain Capital’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,000	Closed	-$578K	–	49
2017 Q3	$578K	Sell	10,000 -1,500	-13%	-$85.2K	0.27%	43
2017 Q2	$679K	Sell	11,500 -11,000	-49%	-$622K	0.28%	44
2017 Q1	$1.24M	Sell	22,500 -23,125	-51%	-$1.25M	0.37%	48
2016 Q4	$2.4M	Buy	+45,625	New	+$2.44M	0.5%	45

Other funds holding PPH

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Colrain Capital's PPH Position: Q4 2017 in Review

Colrain Capital sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2017, closing a stake of 10,000 shares — an estimated $578K sold.

Colrain Capital first reported a position in PPH in Q4 2016 and held it in 4 quarters. The position peaked at $2.4M in Q4 2016. 50 funds tracked by Wall St. Rank hold PPH as of Q4 2017.

Colrain Capital reported no remaining VanEck Pharmaceutical ETF position as of Q4 2017 after selling out during the quarter.
Colrain Capital sold 10,000 VanEck Pharmaceutical ETF shares in Q4 2017, an estimated $578K.
Colrain Capital first reported a position in VanEck Pharmaceutical ETF in Q4 2016 and held it in 4 quarters.
Colrain Capital's VanEck Pharmaceutical ETF position peaked at $2.4M in Q4 2016.
50 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2017.

Based on Colrain Capital's 13F filing for Q4 2017, filed 7 Feb 2018.